This proposal is a part of an integrated project to test the efficacy of three candidate anxiolytics (two structurally unrelated CRr-^ receptor antagonists GSK008 and CRF-002, and a 5HTiA/iB/io receptor antagonist, GSK-1, provided by GlaxoSmithKline (GSK) as part of The Emory-MSSM-GSK-NIMH Collaborative Mood Disorders Initiative, using fear-potentiated startle. The anti-fear and anxiolytic activity of these compounds will be evaluated in healthy subjects using models of phasic (fear) and sustained (anxiety) aversive states derived from humans and from pre-clinical studies in rodents. Two experimental models will be implemented;one based on an instructed fear learning procedure and the other using Pavlovian cued and context conditioning in a computer-generated virtual reality environment, which will also enable us to examine behavioral avoidance. Both procedures are designed to distinguish between phasic fear and sustained anxiety, which according to pre-clinical studies (Dr. Davis, Project 1) are mediated by distinct neural systems. We will examine the potentiation of startle during anticipation of no-shock, predictable shock signaled by a discrete threat cue, and unpredictable shock. Fear-potentiated startle to the discrete threat cue will model phasic fear, whereas the potentiation of startle in the predictable and unpredictable shock conditions will model sustained contextual anxiety. A central goal of this project is to examine whether the GSK compounds are anxiolytic in these models, which have been shown to detect the anxiolytic activity of established anxiolytics (alprazolam, a benzodiazepine, and escitalopram an SSRI). Another goal is to identify different psychopharmacological profiles for phasic fear versus sustained anxiety. Given the prevalence of anxiety disorders in women compared to men, an exploratory aim will be to examine whether sex differences exist with respect to the sensitivity of our anxiety model to treatment with the GSK compounds. These same GSK compounds will also be evaluated in other laboratories (Projects 1 and 5) (separate applications), providing a translational approach to screening and evaluating the efficacy of new compounds. Dr. Davis'preclinical project (Project 1), which is particularly complementary to the present project, will use similar behavioral models in rodents based on startle as an operational measure of fear and anxiety. Drs. Rothbaum and Charney's project (Project 5) will test the clinical efficacy of GSK008 in posttraumatic stress disorder. These parallel projects will provide a test of the predictive validity of the human and animal models. It is hoped that this integrated effort will ultimately lead to development and validation of models for rapid evaluation of novel therapeutics.

Public Health Relevance

There is currently great dissatisfaction with the scientific process through which a drug is transformed from a discovery into a psychopharmacological treatment. The primary goal of this NCDDG Center is to accelerate the development of novel drugs for the treatment of depression and anxiety. The goal of this project (Project 4 of the Center) is to validate experimental models to test potential anxiolytics in healthy participants.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19MH069056-10
Application #
8522311
Study Section
Special Emphasis Panel (ZMH1-ERB-S)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
10
Fiscal Year
2013
Total Cost
$191,676
Indirect Cost
$83,347
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Kilts, Clint D; Kennedy, Ashley; Elton, Amanda L et al. (2014) Individual differences in attentional bias associated with cocaine dependence are related to varying engagement of neural processing networks. Neuropsychopharmacology 39:1135-47
Kaye, Joanna L; Dunlop, Boadie W; Iosifescu, Dan V et al. (2014) Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports. J Psychiatr Res 57:51-7
Dunlop, Boadie W; Rothbaum, Barbara O; Binder, Elisabeth B et al. (2014) Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials 15:240
Sink, K S; Chung, A; Ressler, K J et al. (2013) Anxiogenic effects of CGRP within the BNST may be mediated by CRF acting at BNST CRFR1 receptors. Behav Brain Res 243:286-93
Zoellner, Lori A; Rothbaum, Barbara O; Feeny, Norah C (2011) PTSD not an anxiety disorder? DSM committee proposal turns back the hands of time. Depress Anxiety 28:853-6
Sink, Kelly S; Walker, David L; Yang, Yong et al. (2011) Calcitonin gene-related peptide in the bed nucleus of the stria terminalis produces an anxiety-like pattern of behavior and increases neural activation in anxiety-related structures. J Neurosci 31:1802-10
Mathew, Sanjay J; Vythilingam, Meena; Murrough, James W et al. (2011) A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol 21:221-9
Martin, Elizabeth I; Ressler, Kerry J; Binder, Elisabeth et al. (2010) The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Clin Lab Med 30:865-91
Binder, E B; Nemeroff, C B (2010) The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry 15:574-88
Martin, Elizabeth I; Ressler, Kerry J; Jasnow, Aaron M et al. (2010) A novel transgenic mouse for gene-targeting within cells that express corticotropin-releasing factor. Biol Psychiatry 67:1212-6

Showing the most recent 10 out of 35 publications